内部控制审计报告 山东宝莫生物化工股份有限公司 二〇二三年度 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内 部控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是 山东宝莫公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发 表审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 致同会计师事务所(特殊普通合伙) Thornton 40 日 内部控制审计报告 致同审字（2024）第 110A013732 号 山东宝莫生物化工股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了山东宝莫生物化工股份有限公司(以下简称 山东宝莫公司)2023年 12月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 中国注册会计师 中国注册会计师 赵雷 励 ty Am 110001590134 中国注册会计师 主册会计师 110101560929 二〇二四年四月二十五日 赵雷励 在 * 故雪用 Full nam t Sex 夏 出口上 1982-11- x (* * *** ...

公司全资子公司成都宝莫矿业有限公司（下称"成都宝莫"）与成都磐石 矿业合伙企业（有限合伙）共同投资醴陵市日景矿业发展有限公司（下称"日 景矿业"）构成关联方共同投资事项，现因日景矿业铁石尖金矿项目资源情况复 杂，需投入更多勘探工程及资金，且项目建设进度不及预期，投产时间一再递 延，至今未能获取《安全生产许可证》等原因，公司认为项目现状已与此前既 定投资目标出现重大偏差，为降低公司投资风险，维护投资者权益，公司拟与 交易对手签署股权回购协议，要求交易对手回购成都宝莫所持日景矿业的全部 股权。 山东宝莫生物化工股份有限公司 独立董事关于第六届董事会第十一次会议 相关事项的事前认可意见 根据中国证监会《上市公司独立董事管理办法》、《深圳证券交易所股票上 市规则》、《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范 运作》等规范性文件和公司章程的规定，作为公司第六届董事会的独立董事， 本着认真、负责的态度，基于独立、审慎、客观的立场，对第六届董事会第十 一次会议拟审议的相关议案进行了事前审核，现发表事前认可意见如下： 我们认为，上述投资事项实施前，公司对日景矿业进行了地质、财务、法 律方面的全面尽职调查 ...

致同会计师事务所（特殊普通合伙） 目 录 关于山东宝莫生物化工股份有限公司非经营性资金占用及其他关 联资金往来的专项说明 关于山东宝莫生物化工股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 山东宝莫生物化工股份有限公司 2023 年度非经营性资金占用及其 他关联资金往来情况汇总表 1 t Thornton 中日 关于山东宝莫生物化工股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字(2024)第 110A009010 号 山东宝莫生物化工股份有限公司全体股东: 我们接受山东宝莫生物化工股份有限公司(以下简称"山东宝莫公司")委 托,根据中国注册会计师执业准则审计了山东宝莫公司 2023年 12月 31日的合并 及公司资产负债表,2023年度合并及公司利润表、合并及公司现金流量表、合并 及公司 股东 权益 变 动 表 和 财 务 报 表 附 注,并出 具 了 致 同 审 字 ( 2024 ) 第 110A013738 号无保留意见审计报告。 根据《上市公司监管指引第 8 号 -- 上市公司资金往来、对外担保的监管要 求》等有关规定,山东宝莫公司编制了本专项说明所附的山东宝莫生物化 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 134,389,767.07, representing a 36.57% increase compared to CNY 98,407,036.72 in the same period last year[5] - Net profit attributable to shareholders was CNY 6,526,072.15, a significant increase of 266.31% from a loss of CNY 3,923,995.10 in the previous year[5] - Basic and diluted earnings per share improved to CNY 0.0107, compared to a loss of CNY 0.0064 in the previous year, marking a 267.19% increase[5] - Total operating revenue for Q1 2024 reached CNY 134,389,767.07, an increase of 36.5% compared to CNY 98,407,036.72 in Q1 2023[25] - Net profit for Q1 2024 was CNY 6,526,072.15, a significant recovery from a net loss of CNY 3,923,995.10 in Q1 2023[26] - Earnings per share for Q1 2024 were CNY 0.0107, compared to a loss per share of CNY 0.0064 in the previous year[27] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 61.73% to CNY 11,804,765.86, down from CNY 30,844,660.76 in the same period last year[12] - The net cash flow from operating activities for the current period is ¥11,804,765.86, a decrease of 61.7% compared to ¥30,844,660.76 in the previous period[30] - Total cash inflow from operating activities is ¥123,300,275.03, down 40% from ¥205,839,435.45 in the previous period[30] - Cash outflow from operating activities is ¥111,495,509.17, a decrease of 36.2% compared to ¥174,994,774.69 in the previous period[30] - The net cash flow from investment activities is -¥2,116,764.65, slightly improved from -¥2,187,566.80 in the previous period[30] - Cash inflow from financing activities is ¥0, compared to ¥14,950,000.00 in the previous period[30] - Cash outflow from financing activities is ¥5,694,340.00, down 46.5% from ¥10,619,965.32 in the previous period[30] - The net increase in cash and cash equivalents is ¥3,993,661.21, significantly lower than ¥32,987,128.64 in the previous period[30] - The ending balance of cash and cash equivalents is ¥267,824,578.30, compared to ¥273,576,153.84 in the previous period[30] - As of March 31, 2024, the company's cash and cash equivalents amounted to RMB 270,096,109.98, an increase from RMB 267,083,996.53 at the beginning of the period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 965,517,028.39, a slight increase of 0.14% from CNY 964,151,009.85 at the end of the previous year[5] - Total liabilities decreased to CNY 82,505,873.14 in Q1 2024 from CNY 87,093,868.75 in Q1 2023, reflecting a reduction of 5.9%[23] - The company reported a decrease in short-term borrowings to CNY 16,930,000.00 from CNY 21,880,000.00, a reduction of 22.5% year-over-year[23] - The company has reported a significant decrease in notes receivable from RMB 12,438,054.91 to RMB 1,691,950.59, suggesting a tightening of credit terms or collection efforts[21] Operational Costs - The company reported a 32.60% increase in operating costs compared to the same period last year[11] - Total operating costs for Q1 2024 were CNY 127,208,640.83, up 24.2% from CNY 102,451,591.75 in the same period last year[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,919[14] Strategic Initiatives - The company has initiated a buyback request for its shares in Daying Mining due to project delays and complexities, indicating a strategic shift to mitigate investment risks[18] - A control transfer agreement was signed on October 31, 2023, for 15.8% of the company's shares, with the actual control changing to Luo Xiaolin and Han Ming couple as of January 5, 2024[19] - The company has completed the registration of the change in control, which may impact future strategic directions and governance[19] - The company plans to adjust its performance commitment scheme and provide financial support to its wholly-owned subsidiaries, reflecting a focus on internal growth and stability[17] - The company is actively pursuing new acquisition opportunities and has made adjustments to its financial strategies to enhance operational efficiency[18] Legal Matters - The company is involved in a legal dispute regarding a RMB 13 million equity transfer agreement with Xian Dao Pharmaceutical, with ongoing court proceedings and a ruling received on August 23, 2023[16] - The company has disclosed ongoing litigation and enforcement actions against Xian Dao Pharmaceutical, highlighting potential financial implications and risks associated with the equity transfer[16] Research and Development - Research and development expenses for Q1 2024 were CNY 4,500,835.98, slightly down from CNY 4,849,612.39 in Q1 2023[26] Accounting and Auditing - The company has not undergone an audit for the first quarter report[32] - The company has adopted new accounting standards starting from 2024[31]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2023, reflecting a year-on-year growth of 15%[20]. - The company's operating revenue for 2023 was CNY 387,338,190.19, a decrease of 34.60% compared to CNY 592,284,770.21 in 2022[21]. - The net profit attributable to shareholders was CNY 29,630,378.1, reflecting a significant decline of 82.38% from the previous year's CNY 17,948,109.8[21]. - Basic earnings per share dropped to CNY 0.0086, down 82.27% from CNY 0.0293 in the previous year[21]. - The company reported a net profit of CNY 5,468,510.01 in Q4 2023, marking a recovery from losses in the earlier quarters[27]. - The company achieved operating revenue of CNY 387,338,190.19, a decrease of 34.60% compared to the previous year[46]. - Net profit attributable to shareholders was CNY 5,233,314.15, down 82.38% year-on-year, primarily due to a reduction in customer orders for chemical products[46]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a growth of 20% compared to the previous year[100]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.1 RMB per 10 shares to all shareholders, based on a total of 612,000,000 shares[4]. - The company plans to distribute a cash dividend of CNY 0.1 per 10 shares (including tax), totaling CNY 6,120,000.00, which represents 100% of the profit distribution[123]. - The total number of shares outstanding is 612,000,000, with 99.99% being unrestricted shares[189]. - The largest shareholder, Tibet Taiyi Feng Information Technology Co., Ltd., holds 15.80% of the shares, totaling 96,698,000 shares[191]. - The company has no foreign institutional shareholders, and all shares are held by domestic investors[189]. Strategic Partnerships and Acquisitions - The company has announced a strategic partnership with Sichuan Xingtianfu Hongling Enterprise Management Co., Ltd., which will involve the transfer of 15.8% of its shares[19]. - The company completed the acquisition of a 36% stake in Liling Rijing Mining Development Co., Ltd., which is now a subsidiary of Chengdu Baomo[184]. - The company signed a framework agreement for the transfer of control to Xizang Taiyifeng, involving 96,698,030 shares, representing 15.8% of total shares, with the transfer completed by January 5, 2024[181]. Operational Changes and Risks - The company has identified various operational risks in its annual report, which are detailed in the management discussion and analysis section[4]. - The company has acknowledged uncertainties regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the past three years[22]. - The company faces risks related to oil price fluctuations, high customer concentration, raw material price volatility, and exchange rate changes, which could impact business performance[88]. Research and Development - The company is enhancing innovation capabilities and optimizing resource allocation to explore new fields and industries, aiming to cultivate new profit growth points[35]. - The company has developed new products such as high-performance crude oil viscosity reducers and various polymer products, indicating a strong focus on R&D and industrial application[35]. - The company is developing a new type of polyacrylamide production process, targeting a molecular weight of 25-40 million and a hydrolysis degree of 50-80%[65]. - The company completed the development of a multi-functional fatty amide for enhanced oil recovery, aiming to reduce interfacial tension below 10-3 mN/m[63]. Environmental and Safety Compliance - The company has achieved certification for its occupational health and safety management system and environmental management system[148]. - The company has no recorded administrative penalties for environmental issues during the reporting period[147]. - The wastewater treatment facility has a processing capacity of 35 tons per hour and operates normally, with pre-treated wastewater transported to Sinopec for further purification[143]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local ecological environment bureau[144]. Governance and Management - The company emphasizes strict compliance with regulatory requirements and internal control systems to ensure governance and operational integrity[86]. - The company is committed to enhancing its corporate governance and has appointed two new independent directors to strengthen oversight[104]. - The board of directors held six meetings in 2023, addressing various operational and financial matters, including quarterly reports and environmental project agreements[92]. - The company has established an independent financial department with its own accounting system and tax obligations, ensuring financial autonomy[96]. Market Expansion and Sales - The company is actively pursuing market expansion in North America, Southeast Asia, and Central Asia, indicating a strategic focus on international markets[34]. - The company plans to enhance customer service and product quality to seek new growth points in overseas markets[54]. - The company intends to deepen international market expansion, particularly in North America, the Middle East, and Southeast Asia, through increased participation in international exhibitions and e-commerce platforms[85]. Financial Management - The company has not engaged in any securities or derivative investments during the reporting period[78]. - The company has not reported any penalties or rectification measures during the reporting period[161]. - The company has not experienced any major litigation or arbitration matters during the reporting period[159]. - The company has not made any changes to the scope of consolidated financial statements compared to the previous year[156].

山东宝莫生物化工股份有限公司 二、本人符合中国证监会《上市公司独立董事规则》规定的独立董事任职资 格和条件。 是 □否 三、本人符合该公司章程规定的独立董事任职条件。 是 □ 否 四、本人已经参加培训并取得证券交易所认可的相关证书。 □ 是 否 本人已承诺参加最近一次独立董事培训并取得深圳证券交易 所认可的独立董事资格证书。 独立董事候选人声明 声明人 王雁 作为山东宝莫生物化工股份有限公司第七届董事会独立董事 候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关 系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务 规则对独立董事候选人任职资格及独立性的要求，具体声明如下： 一、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任 公司董事的情形。 是 □ 否 九、本人担任独立董事不会违反中国人民银行《股份制商业银行独立董事和 外部监事制度指引》的相关规定。 是 □ 否 十、本人担任独立董事不会违反中国证监会《证券公司董事、监事和高级管 理人员任职资格监管办法》的相关规定。 五、本人担任独立董事不会违反《中华人民共和国公务员法》的相关规定。 是 □ 否 六、本人 ...

山东宝莫生物化工股份有限公司 2023 年度独立董事述职报告 根据《中华人民共和国公司法》、《上市公司治理准则》和《上市公司独立 董事管理办法》等法律法规以及《独立董事制度》的规定，本人作为山东宝莫 生物化工股份有限公司（下称"公司"或"上市公司"）的独立董事，现向董事 会和股东大会提交年度述职报告，对履行职责的情况进行说明，请予审查。 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人郭忠林，中国国籍，工学硕士研究生，无境外居留权。1986 年至今， 任昆明理工大学采矿工程教授，研究所所长。2012 年至 2020 年任香港上市的 "中国多金属矿业有限公司"（股票代码：02133）技术顾问和首席技术官。 2017 年至 2021 年兼任云南黄金矿业集团股份有限公司第六届和第七届董事会独 立董事。2022 年 6 月至今，担任公司独立董事。除在公司任职之外，未兼任其 他境内外上市公司的独立董事职务。 （二）不存在影响独立性的情况 本人不在公司担任除董事外的其他职务，与公司及其主要股东不存在直接 或者间接利害关系，或者其他可能影响自身进行独立客观判断的关系，能够独 立履职，不受公司及其主要股东等单位或者个 ...

山东宝莫生物化工股份有限公司 按照《上市公司独立董事管理办法》、《深圳证券交易所股票上市规则》 （2023 年 8 月修订）、《深圳证券交易所上市公司自律监管指引第 1 号—主板上 市公司规范运作》（2023 年 12 月修订）以及《山东宝莫生物化工股份有限公司 章程》等相关法律法规、规范性文件对独立董事独立性情况做出的明确规定， 山东宝莫生物化工股份有限公司（下称"公司"）第六届董事会对独立董事童利 忠先生、郭忠林先生、李宁先生提交的《独立董事独立性自查情况报告》进行 了认真审阅及核查，现就公司三名独立董事独立性自查情况发表专项报告如下： 七、最近十二个月内，独立董事童利忠先生、郭忠林先生、李宁先生及其 各自配偶、父母、子女均不存在违背上述第一项至第六项情况的任何情形； 一、独立董事童利忠先生、郭忠林先生、李宁先生及其各自配偶、父母、 子女、主要社会关系未在公司或者公司附属企业任职； 二、独立董事童利忠先生、郭忠林先生、李宁先生及其各自配偶、父母、 子女不是公司前十名股东中的自然人股东，也未直接或间接持有公司已发行总 股本百分之一以上的股份； 六、独立董事童利忠先生、郭忠林先生、李宁先生及其各自配偶、父母、 ...

独立董事提名人声明 提名人山东宝莫生物化工股份有限公司第六届董事会现就提名 王雁 为山 东宝莫生物化工股份有限公司第七届董事会独立董事候选人发表公开声明。被提 名人已书面同意出任山东宝莫生物化工股份有限公司第七届董事会独立董事候 选人。本次提名是在充分了解被提名人职业、学历、专业资格、详细的工作经历、 全部兼职等情况后作出的，本提名人认为被提名人符合相关法律、行政法规、部 门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独 立性的要求，具体声明如下： 山东宝莫生物化工股份有限公司 一、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 是 □ 否 二、被提名人符合中国证监会《上市公司独立董事规则》规定的独立董事任 职资格和条件。 是 □ 否 三、被提名人符合公司章程规定的独立董事任职条件。 是 □ 否 四、被提名人已经参加培训并取得证券交易所认可的相关证书。 □ 是 否 被提名人已承诺参加最近一次独立董事培训并取得深圳证券 交易 所认可的独立董事资格证书。 五、被提名人担任独立董事不会违反《中华人民共和国公务员法》的相关规 定。 是 □ 否 是 □ 否 九 ...

证券代码：002476 证券简称：宝莫股份 公告编号：2024-010 山东宝莫生物化工股份有限公司 关于全资子公司向银行申请综合授信额度的公告 宝莫环境拟以部分自有房产、土地使用权、无形资产及其他资产向相关银行 抵押并申请合计不超过人民币 10,000 万元综合授信额度；申请授信的有效期为 1 年；授信期限内，授信额度可循环使用，各银行实际授信额度可在总额度范围 内相互调剂。 新疆宝莫拟以部分自有房产、设备、土地使用权及其他资产向相关银行抵押 并申请合计不超过人民币 5,000 万元综合授信额度；申请授信的有效期为 1 年； 授信期限内，授信额度可循环使用，各银行实际授信额度可在总额度范围内相互 调剂。 成都宝莫拟以自有资产向相关银行抵/质押并申请合计不超过人民币 20,000 万元综合授信额度；申请授信的有效期为 1 年；授信期限内，授信额度可循环使 用，各银行实际授信额度可在总额度范围内相互调剂。 上述授信总额最终以相关银行实际审批的授信额度为准，在此额度内由公司 子公司依据实际资金需求进行银行借贷。 二、子公司基本情况 （一）宝莫环境基本情况 1、公司名称：东营宝莫环境工程有限公司 本公司及董事会全体 ...